Pharmaceuticals company Ami Organics announced Q1FY25 results: Revenue from operations for Q1FY25 grew by 14.9% YoY to Rs 1,767 million The gross margin for the quarter was at 42.1%. EBITDA for the quarter came at Rs 295 million down 13.2% YoY compared to Rs 340 million in Q1FY24. EBITDA margin for the quarter was at 16.7% as compared to 22.1% in Q1FY24. EBITDA margins contracted due to lower gross margins coupled with higher employee expenses led by annual increments as well as new hiring for Ankleshwar plant. PAT for the quarter was Rs 147 million. PAT margin for the quarter was 8.3%. PAT margins were impacted due to higher finance cost as well as higher depreciation cost. Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am pleased to report that we continue to successfully navigate the challenging industry landscape, achieving strong revenue of ?176 crore, which represents a 14.9% year-over-year growth. This growth was primarily driven by our core pharmaceutical business, while the specialty chemicals segment saw a modest 10% increase. During the quarter, we also successfully completed the Good Manufacturing Practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan, with no critical or major observations. To our knowledge, we may be the only company in India to have successfully passed both USFDA and PMDA inspections in the advanced pharmaceutical intermediate sector. Historically, Q1 is always lowest quarter in terms of revenue each financial year since inception, and we typically see sequential growth from Q1 to Q4. I anticipate similar strong sequential growth in the coming quarters. Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year.” Result PDF
Pharmaceuticals company Ami Organics announced Q4FY24 & FY24 results: Revenue from operations for Q4FY24 grew by 20.7% YoY and 35.2% QoQ to Rs 2,250 million The gross margin for the quarter was at 40.0%. Gross margins were impacted due to change in product mix. EBITDA for the quarter came at Rs 432 million up 5.9% YoY compared to Rs 408 million in Q4FY23 and up 62.8% QoQ compared to Rs 265 million in Q3FY24. EBITDA margin for the quarter was at 19.2% as compared to 21.9% in Q4FY23 and 15.9% in Q3FY24. EBITDA margins contracted by 269bps YoY and grew by 326 bps sequentially. Adjusted PAT for the quarter was Rs 260 million. Adjusted PAT margin for the quarter was 11.6%. Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am pleased to share that we have been successful in navigating through the tough industry scenario to deliver an all-time high quarterly revenue from operations of Rs 225 crore. This represents a growth of 21% YoY and an exceptional 35% sequential growth. Our advanced pharmaceuticals business, grew strongly by 18% YoY and 47% QoQ while our specialty chemicals business grew robustly by 36% YoY during the quarter. I am delighted to share that we have achieved the 'Gold Medal' accreditation from EcoVadis. Although we are in chemicals manufacturing industry, we remain steadfast on our sustainability goals propelled by an intensified focus on green chemistry and green initiatives. This commitment underscores our proactive approach to environmental responsibility and sustainability. I am also thrilled to inform you that recently we have received grant of 3 process patents from The Patent Office, Government of India. Two of these three products are niche and complex in nature. Overall, I believe that we have navigated industry challenges adeptly in FY24 and as we progress ahead with improved overall prospects for the industry, we firmly believe we will sustain our growth trajectory, targeting a revenue growth in range of 20-25% for the fiscal year FY25.” Result PDF